Rapamycin (mTORC1 inhibitor) reduces the production of lactate and 2-hydroxyglutarate oncometabolites in IDH1 mutant fibrosarcoma cells

Abstract Background Multiple studies concluded that oncometabolites (e.g. D-2-hydroxyglutarate (2-HG) related to mutant isocitrate dehydrogenase 1/2 (IDH1/2) and lactate) have tumour promoting potential. Regulatory mechanisms implicated in the maintenance of oncometabolite production have great inte...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Zoltán Hujber, Gábor Petővári, Norbert Szoboszlai, Titanilla Dankó, Noémi Nagy, Csilla Kriston, Ildikó Krencz, Sándor Paku, Olivér Ozohanics, László Drahos, András Jeney, Anna Sebestyén
Formato: Artigo
Idioma:Inglês
Publicado em: BMC 2017-06-01
Colecção:Journal of Experimental & Clinical Cancer Research
Assuntos:
Rapamycin
mTOR
Oncometabolite
2-hydroxyglutarate
Lactate
Tumour metabolism
Acesso em linha:http://link.springer.com/article/10.1186/s13046-017-0544-y
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados